Overexpression of p16ink4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri

International Journal of Cancer

Volumn 92, Issue 2, 2001, Pages 276-284

  Klaes, Ruediger ^a   Friedrich, Tibor ^a   Spitkovsky, Dimitry ^a   Ridder, Ruediger ^b   Rudy, Wolfgang ^b   Petry, Ulrich ^b   Dallenbach Hellweg, Gisela ^c   Schmidt, Dietmar ^c   Von Doeberitz, Magnus Knebel ^a,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MTM Laboratories AG   (Germany)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^d Institute of Pathology   (Germany)

Author keywords

Cervical neoplasia; Diagnostic marker; Human papillomavirus; p16INK4a

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; MONOCLONAL ANTIBODY; TUMOR MARKER; VIRUS DNA;

ARTICLE; CANCER CELL; CANCER SCREENING; CELL CYCLE; ENZYME IMMUNOASSAY; EPITHELIUM CELL; GENE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PAPANICOLAOU TEST; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VIRUS ONCOGENE; VIRUS TYPING; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PAPILLOMAVIRIDAE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS;

EID: 0035871985     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1174     Document Type: Article

References (64)

1. Estimates of the worldwide incidence of eighteen major cancers in 1985
2. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma
3. Interim guidelines for management of abnormal cervical cytology
4. Trends in mortality from cervical cancer in the Nordic countries: Association with organised screening pmgrammes
5. Organisation and results of the cervical cytology screening programme in British Columbia, 1955-85
6. Screening for cervical cancer
7. Cancer in the European Community and its member states
8. The Papanicolaou smear: Its value and limitations
9. Epidemiology of cervical cancer
10. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer
11. Screening for cervical cancer
12. Cervical screening adjuncts: Recent advances
13. Cost-effectiveness of rescreening conventionally prepared cervical smears by PAPNET testing
14. Emerging technologies and cervical cancer
15. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial
16. Inter- and intra-observer variation in the histopathological reporting of cervical intraepithelial lesions using a modified Bethesda grading system
17. Assessment of Ki-67 antigen immunostaining in squamous intraepithelial lesions of the uterine cervix. Correlation with the histologic grade and human papillomavirus type
18. Viral and histopathologic correlates of MN and MIB-1 expression in cervical intraepithelial neoplasia
19. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type
20. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication
21. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas
22. Expression of the MN antigen in cervical Papanicolaou smears is an early diagnostic biomarker of cervical dysplasia
23. Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia
24. A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN
25. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia
26. Papillomaviruses in human cancers
27. Papillomaviruses causing cancer: Evasion from hostcell control in early events in carcinogenesis
28. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
29. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells
30. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: Analysis by in situ hybridization
31. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
32. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product
33. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity
34. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins
35. Cancer cell cycles
36. Abhormal cell cycle regulation in malignancy
37. Rb function in cell-cycle regulation and apoptosis
38. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
39. A cell cycle regulator potentially involved in genesis of many tumor types
40. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
41. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
42. Germline p16 mutations in familial melanoma
43. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma
44. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
45. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas
46. INKa gene in human ovarian cancers
47. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis
48. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb
49. Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma
50. Alteration of p16 and p15 genes in human uterine tumours
51. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis
52. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions
53. Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia
54. Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the 'Ki- 67' proteins
55. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions
56. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia
57. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR
58. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus geno-types in cervical scrapings
59. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product
60. CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines
61. p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines
62. p16INK4 and p15INK4B alterations in primary gynecologic malignancy
63. INK4a gene alterations in primary cervical carcinoma tissues and cell lines with human papillomavirus infection